Corporate Magazine 2012 - Boehringer Ingelheim

product portfoliobranded prescription medicinesIndications Brand names Active ingredients• Essential hypertension• Cardiovascular preventionmicardis®micardisplus®micardis® plusmicardis® hctco-micardis®telmisartan;telmisartan, hydrochlorothiazideTreatment of essential hypertension.For the reduction of the risk of myocardialinfarction (heart attack), stroke ordeath from cardiovascular (CV) causes inpatients 55 years of age or older at highrisk of developing major CV events whoare unable to take ACE inhibitors (USA).For the reduction of cardiovascular morbidityin patients with manifest atherothromboticcardiovascular disease (historyof coronary heart disease, stroke orperipheral arterial disease), or type 2diabetes mellitus with documented targetorgan damage (EU).• Hypertensiontwynsta®micamlo®micardis amlo®micardis anlo®micardis duo®micardis® duotelmisartan, amlodipineTreatment of hypertension alone or withother antihypertensive agents. As initialtherapy in patients likely to need multipleantihypertensive agents to achievetheir blood pressure goals (USA).Add-on therapy in adult patients with notadequately controlled blood pressure onamlodipine and replacement therapy inadult patients receiving telmisartan andamlodipine from separate tablets (EU).• Secondary prevention ofstroke or transient ischaemicattacks (TIA)aggrenox®agrenox®asasantin®asasantin® retarddipyridamole,acetylsalicylic acidPrevention of stroke following a firststroke or transient ischaemic attacks.• Hypertensioncatapresan®catapres®catapressan®atensina®clonidineAll forms of high blood pressure, unlesscaused by phaeochromocytoma.• Acute ischaemic stroke• Acute myocardial infarction• Acute massive pulmonaryembolism• Catheter clearance due tothrombotic occlusionactilyse®actilyse® cathflo® 2mgalteplaseFibrinolytic treatment of acute ischaemicstroke, acute myocardial infarction,acute massive pulmonary embolism andfor catheter clearance due to thromboticocclusion.Cardiovascular diseases75